With deep experience in FDA consulting and health policy consulting, we advise patient advocates, global life science and innovative emerging companies on product approvals and regulatory reforms, drafting and enacting Federal legislation, and securing funding or creating new P3s - we've accomplished it all...
Offering 30+ years of Federal health
policy and legislative insights, as former congressional committee staff, policy advisor, and leader of national FDA law and Federal affairs practices
We publish regularly on health policy: read our Dec 2023 Milbank Quarterly essay on the Orphan Drug Act's 40th anniversary and our Feb 2023 Health Affairs Forefront views on mifepristone.
We can help develop effective strategies to engage Federal agencies like HHS, FDA, NIH, CDC, ARPA-H and BARDA.
Our clients include/have included Fortune 100 biopharmas, leading patient groups, advocacy coalitions, life science trade associations, and innovators in Europe, South Korea and Israel.
Our solutions are grounded in sound policy, a clear understanding of the law, and the best clinical evidence - helping advance public health for all.
If your issue is at CMS or requires Federal lobbying, we know trusted consulting partners who are national experts in their domains.
Feel free to call or message with your health policy question. Let's discuss the issue and find some new approaches...
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.